Results 91 to 100 of about 679,466 (304)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Hyponatremia in Cirrhosis: Comparative Evaluation of MELD and MELD-Na Scores for Predicting Short- and Long-Term Mortality

APIK Journal of Internal Medicine
Background: Hyponatremia is a frequent complication in patients with liver cirrhosis and is associated with increased morbidity and mortality. The model for end-stage liver disease (MELD) score is commonly used to predict prognosis in cirrhosis, but does
Goutami V. Kohir, Nagaraj Kotli
doaj   +1 more source

Surgery in Liver Diseases: Perioperative Evaluation & Management [PDF]

, 2016
Many patients with liver disease would have to undergo surgery. Surgery and anesthesia in patients with liver disease are associated with extremely high perioperative complications and mortality.
Kholili, U. (Ulfa), Syalini, D. A. (Denada)   +1 more
core  

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Renal Outcomes in Patients With IgA Nephropathy Undergoing Liver Transplant: A Retrospective Cohort Study

Transplantation Direct, 2017
Background. End-stage liver disease (ESLD) is the most common cause of secondary immunoglobulin A nephropathy (IgAN). Multiple mechanisms have been proposed to explain the association between liver disease and IgAN.
Musab S. Hommos, MBBS, Ziad M. El-Zoghby, MD   +1 more
doaj   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Sarcopenia in Children With End‐Stage Liver Disease

Journal of Pediatric Gastroenterology and Nutrition, 2018
ABSTRACTBackground:Sarcopenia, reflected by decreased psoas muscle surface area (PMSA), has been identified as a novel and independent predictor of wait‐list mortality and outcomes in adult liver transplantation (LT). We hypothesized that children with end‐stage liver disease (ESLD) would have smaller PMSA than healthy controls.Methods:Computer ...
Eberhard, Lurz, Hiten, Patel, Richard G, Frimpong, Amanda, Ricciuto, Mohit, Kehar, Paul W, Wales, Alexander J, Towbin, Govind B, Chavhan, Binita M, Kamath, Vicky L, Ng   +9 more
openaire   +3 more sources

Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome

, 2016
Non-alcoholic fatty liver disease (NAFLD) represents a wide spectrum of liver disease from simple steatosis, to steatohepatitis, (both with and without liver fibrosis), cirrhosis and end-stage liver failure.
Byrne, C.D., Wainwright, P.
core   +2 more sources

Computed tomography measures of nutrition in patients with end-stage liver disease provide a novel approach to characterize deficits [PDF]

, 2018
Aim Patients with cirrhosis and end-stage liver disease (ESLD) develop severe nutrition deficits that impact on morbidity and mortality. Laboratory measures of nutrition fail to fully assess clinical deficits in muscle mass and fat stores.
Bush, Weston J., Davis, Jason P., Kubal, Chandrashekhar A., Maluccio, Mary A., Mangus, Richard S., Salisbury, Jared B.   +5 more
core   +1 more source